GlaxoSmithKline PLC Publication of AGM and GM Shareholder Documents (8665U)
April 02 2019 - 8:00AM
UK Regulatory
TIDMGSK
RNS Number : 8665U
GlaxoSmithKline PLC
02 April 2019
GlaxoSmithKline plc
(the 'Company')
Publication of 2019 Notice of Annual General Meeting and Notice
of General Meeting relating to the proposed Consumer Healthcare
Joint Venture with Pfizer, Inc
The Company will today publish on its website,
www.gsk.com/en-gb/investors/shareholder-information/ the following
documents, which will be distributed to shareholders shortly:
-- 2019 Notice of Annual General Meeting (the '2019 AGM Notice')
-- 2018 Annual Summary
-- Circular and Notice of General Meeting (the 'Circular')
(together, the 'AGM and GM Shareholder documents')
The Company's Annual General Meeting ('AGM') will be held on
Wednesday 8 May 2019 at 2.30pm at the Sofitel London Heathrow,
Terminal 5, London Heathrow Airport, TW6 2GD (the 'Sofitel').
On 19 December 2018, the Company announced that it had reached
an agreement with Pfizer, Inc to combine their consumer health
businesses into a world-leading Joint Venture. The transaction is
subject to the approval of shareholders and the Circular contains a
notice convening a general meeting of the Company to be held at the
Sofitel at 3.30pm on Wednesday 8 May 2019 (or as soon thereafter as
the Company's AGM convened for that date has been concluded or
adjourned).
The transaction is expected to close in the second half of 2019.
Further details of the transaction are set out in the Circular.
In compliance with Listing Rule 9.6.1R of the UK Financial
Conduct Authority, the AGM and GM Shareholder documents will be
submitted to the UK Listing Authority and will, in due course, be
available for inspection at www.morningstar.co.uk/uk/NSM.
V A Whyte
Company Secretary
2 April 2019
GSK - one of the world's leading research-based pharmaceutical
and healthcare companies - is committed to improving the quality of
human life by enabling people to do more, feel better and live
longer. For further information please visit www.gsk.com.
GSK enquiries:
Global Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
Tim Foley +44 (0) 20 8047 (London)
5502
US Media enquiries: Sarah Spencer +1 215 751 3335 (Philadelphia)
Analyst/Investor Sarah Elton-Farr +44 (0) 20 8047 (London)
enquiries: 5194
Danielle Smith +44 (0) 20 8047 (London)
0932
James Dodwell +44 (0) 20 8047 (London)
2406
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Cautionary statement
The release, publication or distribution of this announcement in
jurisdictions other than the United Kingdom may be restricted by
law and therefore any persons who are subject to the laws of any
jurisdiction other than the United Kingdom should inform themselves
about, and observe, any applicable requirements. This announcement
has been prepared for the purposes of complying with the Listing
Rules and the information disclosed may not be the same as that
which would have been disclosed if this announcement had been
prepared in accordance with the laws and regulations of any
jurisdiction outside of England and Wales.
This announcement is not intended to, and does not constitute,
or form part of, any offer to sell or an invitation to purchase or
subscribe for any securities or a solicitation of any vote or
approval in any jurisdiction. GSK shareholders are advised to read
carefully the formal documentation in relation to the transaction
once it has been despatched. Any response to the proposal should be
made only on the basis of the information in the formal
documentation to follow.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBBGDSCXGBGCD
(END) Dow Jones Newswires
April 02, 2019 08:00 ET (12:00 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024